Novartis AG’s MS Pill Gets First Approval in Russia, U.S. and Others May Follow

ZURICH, Sept 10 (Reuters) - Swiss drugmaker Novartis (NOVN.VX) has won its first approval for multiple sclerosis (MS) tablet Gilenya in Russia, raising hopes of U.S. Food and Drug Administration (FDA) approval later this month.